This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kutschke, A.
Right arrow Articles by de Jonge, B. L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kutschke, A.
Right arrow Articles by de Jonge, B. L. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2005, p. 3009-3010, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.3009-3010.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Compound Efflux in Helicobacter pylori

Amy Kutschke and Boudewijn L. M. de Jonge*

Infection Discovery, Cancer and Infection Research Area, AstraZeneca R&D, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451

Received 9 February 2005/ Returned for modification 27 March 2005/ Accepted 28 March 2005

Susceptibility testing with a variety of structurally unrelated compounds showed that hefC in Helicobacter pylori is involved in multidrug efflux. This efflux was shown to depend on the proton motive force, as demonstrated by ethidium bromide accumulation experiments. Thus, H. pylori contains an active multidrug efflux mechanism.

* Corresponding author. Mailing address: Infection Discovery, Cancer and Infection Research Area, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451. Phone: (781) 839-4535. Fax: (781) 839-4500. E-mail: boudewijn.dejonge{at}astrazeneca.com

Antimicrobial Agents and Chemotherapy, July 2005, p. 3009-3010, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.3009-3010.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Anoushiravani, M., Falsafi, T., Niknam, V. (2009). Proton motive force-dependent efflux of tetracycline in clinical isolates of Helicobacter pylori. J Med Microbiol 58: 1309-1313 [Abstract] [Full Text]  
  • de Jonge, B. L. M., Kutschke, A., Uria-Nickelsen, M., Kamp, H. D., Mills, S. D. (2009). Pyrazolopyrimidinediones Are Selective Agents for Helicobacter pylori That Suppress Growth through Inhibition of Glutamate Racemase (MurI). Antimicrob. Agents Chemother. 53: 3331-3336 [Abstract] [Full Text]  
  • Boyanova, L. (2009). Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol 58: 930-935 [Abstract] [Full Text]  
  • Megraud, F., Lehours, P. (2007). Helicobacter pylori Detection and Antimicrobial Susceptibility Testing. Clin. Microbiol. Rev. 20: 280-322 [Abstract] [Full Text]  
  • Nishizawa, T., Suzuki, H., Kurabayashi, K., Masaoka, T., Muraoka, H., Mori, M., Iwasaki, E., Kobayashi, I., Hibi, T. (2006). Gatifloxacin Resistance and Mutations in gyrA after Unsuccessful Helicobacter pylori Eradication in Japan.. Antimicrob. Agents Chemother. 50: 1538-1540 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»